Lv1
38 积分 2024-10-22 加入
RIPK2 as a promising druggable target for autoimmune diseases
10小时前
已完结
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
27天前
已完结
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study
1个月前
已完结
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
1个月前
已完结
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations
1个月前
已完结
Learning CNS immunopathology from therapeutic interventions
1个月前
已完结
Origins and immunopathogenesis of autoimmune central nervous system disorders
1个月前
已完结
Targeted Degradation of the Wiz Transcription Factor for Gamma Globin De-Repression
2个月前
已完结
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model
2个月前
已完结
A new perspective on therapies involving B-cell depletion in autoimmune diseases
2个月前
已完结
皖公网安备34019202002308
